Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab for Debilitating Fibrosing Skin Disorders
NCT00936546Phase 2Completed
- Sponsor
- Ghent University Hospital
- Start
- Jun 2009
- Primary completion
- Jun 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab in localized scleroderma, eosinophilic fasciitis (EF), sponsored by Ghent University Hospital. Started Jun 2009; status: completed.
02
Drugs
rituximab
03
Conditions
localized sclerodermaeosinophilic fasciitis (EF)
Beyond the preview
Go deeper on NCT00936546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00936546.